Connexin Hemichannel Modulators for Post-Acute Infection Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a significant unmet medical need for effective therapeutics to treat and prevent post-acute infection syndromes such as long COVID, long flu, and other chronic symptoms resulting from various infections, as current understanding of these conditions is limited and there are no approved medications available.

Innovation Solution

The use of connexin hemichannel modulators, particularly connexin 43 hemichannel modulators, and inflammasome modulators, specifically NLRP3 inflammasome modulators, to treat, prevent, and alleviate symptoms associated with post-acute infection syndromes, including fatigue, brain fog, neuropathy, and other debilitating symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current conventional treatments are used for post-acute infection syndromes, then standard care is provided, but effective symptom relief and prevention are not achieved

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidavailability of approved medications

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of known compounds to create novel derivatives with enhanced therapeutic properties. Specifically, the invention modifies compounds of Formula I by varying substituents at different positions (R1, R2, R3, R4, R5, R6, R7, R8) to optimize anti-inflammatory and immunomodulatory effects for treating post-acute infection syndromes like long COVID

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by combining multiple therapeutic agents into single pharmaceutical compositions. The invention describes compositions that may include compounds of Formula I in combination with other active ingredients, excipients, and delivery systems to create multi-functional treatments that address multiple symptoms of post-acute infection syndromes simultaneously

Inventive Principle:

Principle #40Composite materials

2Ease of manufacture

If no approved medications are available for post-acute infection syndromes, then research and development can proceed without regulatory constraints, but patients cannot access effective treatments

Engineering Contradiction:

Improveregulatory flexibility for R&DVSAvoidaccess to effective treatments

Core Design Contradiction:

Ease of manufactureVSEase of operation

Solution Approach 1:

The patent applies preliminary action by conducting extensive preclinical research and characterizing the pharmacological properties of compounds of Formula I before clinical application. The invention includes detailed descriptions of in vitro and in vivo studies that demonstrate safety, efficacy, and mechanism of action, preparing the foundation for future clinical trials and regulatory approval

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses intermediary compounds as mediators between known pharmacological agents and therapeutic outcomes. The compounds of Formula I serve as intermediate structures that can be further optimized and combined with other agents to bridge the gap between current conventional treatments and the need for effective post-acute infection syndrome therapies

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250352508A1Prevention and treatment of post-acute infection syndromes

Publication Date: 2025.11.20 INFLAMMX THERAPEUTICS INC

AI summary

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and/or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.